Intelligence · Clinical Development
Pipeline search results
Programs matching “administration” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 43 pipeline programs matching "administration" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Intravenous methylene blue administration
Hospital Authority, Hong Kong
Severe Sepsis
1 trial -
NPC-11 for intravenous or oral administration.
Belpharma s.a.
Apnea of Prematurity
1 trial -
Powder for reconstitution for enteral administration
Lacuna Pharma Pty Ltd
Intestinal Malabsorption
1 trial -
Powder for reconstitution for enteral administration
Lacuna Pharma Pty Ltd
Intestinal Malabsorption
1 trial -
UI022 or UI023 and co-administration of matching placebo
United Therapeutics Europe Ltd
Peripheral Arterial Disease
1 trial -
ALN-TTRSC (revusiran) for subcutaneous administration
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial -
AS01 adjuvant (0.5 mL intramuscular)
Hospital Authority, Hong Kong
Immune System Responses and Trained Immunity After AS01 Administration
1 trial -
Infigratinib is provided as a single dose of minitablets for oral administration
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Intracavernosal administration of autologous ADRC
The First People's Hospital of Lianyungang
Erectile Dysfunction
1 trial -
Intravenous administration of 1 million of MSC
Lxo Ireland Designated Activity Company
Amyotrophic Lateral Sclerosis
1 trial -
Ommaya 02
The First People's Hospital of Lianyungang
Leptomeningeal Metastasis of HER2-positive Breast Cancer
1 trial -
PRODIGE 107-ENGIC01-COLOSOTO
NORTHWEST BIOTHERAPEUTICS INC
Colorectal Carcinoma
1 trial -
Phosphate buffered saline for SC administration
Alnylam Netherlands B.V.
Type 2 Diabetes Mellitus
1 trial -
TNTL capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Accidental Exposure While Preparing Drug for Administration
1 trial -
Teniposide administration
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
phosphate-buffered saline for SC administration
Alnylam Netherlands B.V.
Hereditary Hemorrhagic Telangiectasia (HHT)
1 trial -
22534
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
AN OPEN-LABEL for Intramuscular administration of…
Lacuna Pharma Pty Ltd
Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.
1 trial -
AVN-944 capsules for oral administration
Vertex Pharmaceuticals (Australia) Pty.
Acute Leukemia
1 trial -
Administration of UI087
United Therapeutics Europe Ltd
Diabetes Mellitus (Type 2)
1 trial -
Administration of the malaria inoculum
CNS Pharmaceuticals
Malaria
1 trial -
BMN 111 administration via Injector Pen
BioMarin Pharmaceutical Australia Pty Ltd
Achondroplasia
1 trial -
Coadministration of GA2 Sporozoites With Adjuvants (CoGA)
Disc Medicine
Falciparum malaria
1 trial -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.